Literature DB >> 3882005

Reversal of captopril-induced psychosis with naloxone.

M A Gillman, R Sandyk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3882005     DOI： 10.1176/ajp.142.2.270a

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  9 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 2.  On the physiology of metazoa.

Authors:  A R Ameen
Journal:  Experientia       Date:  1996-03-15

Review 3.  Hallucinations as an adverse effect of angiotensin converting enzyme inhibition.

Authors:  C A Haffner; B S Smith; C Pepper
Journal:  Postgrad Med J       Date:  1993-03       Impact factor: 2.401

Review 4.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 5.  Drug-induced psychiatric disorders and their management.

Authors:  L E Hollister
Journal:  Med Toxicol       Date:  1986 Nov-Dec

Review 6.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

7.  What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide?

Authors:  Mark A Gillman
Journal:  Front Psychiatry       Date:  2022-08-22       Impact factor: 5.435

8.  Pharmacological Hypotension as a Cause of Delirious Mania in a Patient with Bipolar Disorder.

Authors:  Manuel Glauco Carbone; Mario Miniati; Marly Simoncini; Beniamino Tripodi; Claudia Tagliarini; Claudia Carmassi; Liliana Dell'Osso
Journal:  Case Rep Psychiatry       Date:  2017-12-19

Review 9.  Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review.

Authors:  John Doane; Barry Stults
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-01-25       Impact factor: 3.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.